20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
“Cancer Driver Interception” is a unique cancer prevention test market positioning. The concept involves identifying and intercepting the key “drivers”, namely those physiological or pathophysiological conditions that trigger or accelerate cancer development. BIOSCIENCE GENOMICS focuses on cancer driver interception and likely relies on advanced molecular technologies such as next-generation sequencing to detect and monitor the presence of cancer drivers. By aiming to intercept cancer drivers, BIOSCIENCE GENOMICS may be uniquely positioned in the market to offer tests that detect prodromal cancer conditions. Traditional cancer screening tests can only detect existing cancers, whereas we focus on cancer driver interception, which implies a fundamental preventive approach. This concept is relatively new and rapidly evolving, and BIOSCIENCE GENOMICS will shape the future of cancer real prevention.
